European Commission (EC) Approves LIVTENCITYTM? (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
? LIVTENCITY Is the First and Only Treatment Approved for This Indication by the EC1 ? CMV Is One of...




















